Boston Scientific Corporation BDR (B1SX34)
Bovespa
53.28
-1.98 (-3.58%)
Closed
Oct 5, 2026
Day's Range
52.9553.82
52 wk Range
50.29140.91
Financial Statements - B1SX34 - Boston Scientific Corporation BDR
Revenue
20.07B▼ 77.2%
Net Income
2.89B▼ 70.2%Net Margin 14.4%
EBITDA
5.33B▼ 76.6%
Free Cash Flow
3.40B▼ 72.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 20.07B | 87.92B | 14.24B | 12.68B | 11.88B | 9.91B |
| Cost of Goods | 6.22B | 27.59B | 4.34B | 3.95B | 3.71B | 3.51B |
| Gross Profit | 13.85B | 60.32B | 9.89B | 8.72B | 8.17B | 6.40B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 3.97B | 15.76B | 2.41B | 2.03B | 1.82B | 684M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -267M | -2.73B | -188M | -434M | -412M | -405M |
| Pre Tax Income | 3.38B | 11.98B | 1.98B | 1.14B | 1.07B | -79M |
| Income Tax | 493M | 2.28B | 393M | 443M | 36M | 2M |
| Net Income | 2.89B | 9.69B | 1.59B | 698M | 1.04B | -82M |
| EPS Basic | 0.49 | 1.26 | 1.08 | 0.45 | 0.69 | -0.12 |
| EPS Diluted | 0.485 | 1.25 | 1.07 | 0.45 | 0.69 | -0.12 |
| Basic Shares Outstanding | 5.92B | 7.72B | 255.07M | 248.37M | 246.94M | 245.97M |
| Diluted Shares Outstanding | 5.92B | 7.72B | 255.07M | 248.37M | 246.94M | 245.97M |
| Ebit | 3.73B | 13.58B | 2.25B | 1.61B | 1.41B | 282M |
| Ebitda | 5.33B | 22.82B | 3.62B | 3.16B | 2.91B | 1.81B |
| Net Income Continuous Operations | 2.89B | 9.69B | 1.59B | 698M | 1.04B | -82M |
| Minority Interests | 6M | 8M | 1M | 0 | 0 | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
